TORL BioTherapeutics

TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel, antibody-based therapies to transform the lives of cancer patients. Its lead candidate, TORL-1-23, is a CLDN6-directed ADC for patients with various types of cancer. The company also has two other clinical-stage programs: an ADC and an mAb targeting CLDN18.2. Additionally, TORL is advancing a series of novel preclinical ADCs and mAbs for oncology indications with unmet medical needs.